AZD2693 clinical trials
Also written AZD2693.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses AZD2693 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AZD2693
- 5
Studies by the year they started
5 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 2 |
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses AZD2693 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisCompletedPhase 2AstraZenecaNCT05809934Written as AZD2693How we know
- A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693CompletedPhase 1AstraZenecaNCT05919069Written as AZD2693How we know
- Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy ParticipantsCompletedPhase 1AstraZenecaNCT05107336Written as AZD2693How we know
- A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis PatientsCompletedPhase 1AstraZenecaNCT04483947Written as AZD2693How we know
- A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese SubjectsCompletedPhase 1AstraZenecaNCT04142424Written as AZD2693How we know
What changed recently
From the registry's own updates since Oct 23, 2026.